ReFlow Therapeutics AG has been awarded a non-dilutive public grant of over CHF 823'000 from the Swiss Commission for Technology and Innovation. The funds will allow the Company to run their current project over the next 18 months.
Cellestia Biotech AG, a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway, announced the final closing of its seed financing rounds securing a total of CHF 8 million in funding.
ObsEva's common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol “OBSV” on January 26, 2017. Today ObsEva CEO Ernest Loumaye will ring the Nasdaq stock market opening bell in celebration of the IPO.
Johnson & Johnson and Actelion Ltd. today announced that they have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland to acquire all of the outstanding shares of Actelion. Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company which will be listed on the SIX Swiss Exchange.
Innovative und stark wachsende Schweizer Startups haben im vergangenen Jahr 909 Millionen Franken eingesammelt; das sind 35 Prozent mehr als im Vorjahr. Gut die Hälfte des Geldes floss in Unternehmen aus dem Grossraum Lausanne. Besonders erfreulich entwickelte sich der ICT Sektor.
Biowatch SA has successfully closed the seed financing round with CHF 1.2M to finalise the development of their solution. The Lausanne based startup is developing a biometric recognition system that can be integrated any wearable for secure authentication.